Comera Life Sciences Holdings Bilan de santé

Santé financière contrôle des critères 2/6

Comera Life Sciences Holdings possède un total de capitaux propres de $102.3K et une dette totale de $389.9K, ce qui porte son ratio d'endettement à 381.2%. Son actif total et son passif total sont $3.1M et de $3.0M.

Informations clés

381.2%

Ratio d'endettement

US$389.87k

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$1.77m
Fonds propres	US$102.26k
Total du passif	US$2.97m
Total des actifs	US$3.07m

Mises à jour récentes de la santé financière

Recent updates

Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans

May 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CMRA ( $2.6M ) ne couvrent pas ses passifs à court terme ( $2.9M ).

Passif à long terme: Les actifs à court terme de CMRA ( $2.6M ) dépassent ses passifs à long terme ( $37.3K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: CMRA dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de CMRA a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: Données insuffisantes pour déterminer si CMRA dispose de suffisamment de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: Données insuffisantes pour déterminer si CMRA dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.

Comera Life Sciences Holdings Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

The Nasdaq Stock Market to Delist the Common Stock of Comera Life Sciences Holdings

Comera Life Sciences Holdings Receives Notice from the Nasdaq Stock Market

Comera Life Sciences Holdings Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Comera Life Sciences Holdings Receives A Determination Letter from Nasdaq Regarding Market Value of Listed Securities

Comera Life Sciences Holdings Receives Notice from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Comera Life Sciences Holdings Receives a Non-Compliance Letter from the Listing Qualifications Department Staff of Nasdaq

Recent updates

The Nasdaq Stock Market to Delist the Common Stock of Comera Life Sciences Holdings

Comera Life Sciences Holdings, Inc. Announces Chief Executive Officer Changes

Comera Life Sciences Holdings, Inc.(OTCPK:CMRA) dropped from NASDAQ Composite Index

Comera Life Sciences Holdings Receives Notice from the Nasdaq Stock Market

Comera Life Sciences Holdings, Inc. Appoints Dorothy Clarke to Board of Directors

Second quarter 2023 earnings released: US$0.078 loss per share (vs US$1.14 loss in 2Q 2022)

New major risk - Shareholder dilution

Comera Life Sciences Holdings Receives Non-Compliance Notice From The Nasdaq Stock Market LLC

Comera Life Sciences Holdings, Inc. announced that it has received $4.069993 million in funding

Comera Life Sciences Holdings, Inc. Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities

Second quarter 2023 earnings released: US$0.078 loss per share (vs US$1.14 loss in 2Q 2022)

Comera Life Sciences Holdings, Inc., Annual General Meeting, Aug 31, 2023

Comera Life Sciences Holdings, Inc. Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore(TM) Platform

Comera Life Sciences Holdings, Inc. announced that it expects to receive $4.1 million in funding

New major risk - Share price stability

Comera Life Sciences Holdings Receives A Determination Letter from Nasdaq Regarding Market Value of Listed Securities

First quarter 2023 earnings released: US$0.13 loss per share (vs US$3.09 loss in 1Q 2022)

Comera Life Sciences Holdings Receives Notice from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Full year 2022 earnings released: US$1.76 loss per share (vs US$1.40 loss in FY 2021)

Comera Life Sciences Holdings, Inc. Announces Board Resignations

High number of new and inexperienced directors

Comera Life Sciences Holdings Receives a Non-Compliance Letter from the Listing Qualifications Department Staff of Nasdaq

Third quarter 2022 earnings released

Third quarter 2022 earnings released

Comera Life Sciences Appoints Janice Marie Mccourt as Chief Business Officer

Comera Life Sciences Holdings, Inc. Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study

Comera Life Sciences rises on positive preclinical data from Sequrus study

Comera life sciences expands woburn operations

Independent Director recently bought US$102k worth of stock

Comera Life Sciences Holdings, Inc. announced that it expects to receive $15 million in funding from Arena Business Solutions Global SPC II, Ltd

Comera Life Sciences announces up to $15M purchase agreement with Arena

Second quarter 2022 earnings released

Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit

Comera Life Sciences GAAP EPS of -$1.14, revenue of $0.15M

Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient

Comera Life Sciences Holdings, Inc. Appoints Michael Campbell as Executive Vice President

Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines